Shannon Dauksis

Shannon Dauksis is the Senior Director of Program Management at Nuvalent. Prior to joining Nuvalent, Shannon was the Director of Oncology, Synthetic Lethality Pipeline & Project Management at GSK from February 2020 to July 2021. Shannon has also held positions as the Director | Global Development Project Lead - Immuno-Oncology at EMD Serono, Inc. from November 2015 to February 2020, the Associate Director of Program Management at Verastem from September 2014 to November 2015, and the Program Manager at ZIOPHARM Oncology, Inc. from May 2012 to September 2014. Shannon began their career as a Per Diem Staff Pharmacist at University of Rhode Island in September 2013 and continued in that role until August 2014. Shannon has a wealth of experience in the field of oncology and brings a wealth of knowledge and expertise to their current role at Nuvalent.

Shannon Dauksis graduated from the University of Rhode Island with a Doctor of Pharmacy degree and is currently certified as a Registered Pharmacist in Rhode Island and Providence Plantations, Commonwealth of Massachusetts, and American Pharmacists Association.

Their manager is James Porter, CEO. They work with Jessie Lin - VP, Corporate Strategy & Portfolio Management, Alex Balcom - CFO, and John Soglia - VP, Translational Development.